Louise Stanton

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

Ellen Copson, Tom Maishman, William Tapper et al. · The Lancet Oncology · 2018 · 495 citations · Full text

Medicine, Genetics, Oncology +7

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

John Primrose, Stephen Falk, Meg Finch-Jones et al. · The Lancet Oncology · 2014 · 433 citations

Medicine, Oncology, Pharmacotherapy +16

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 272 citations · Full text

Medicine, Hematology, Oncology +15

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

John Bridgewater, S. Pugh, Tom Maishman et al. · The Lancet Oncology · 2020 · 239 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study

Ellen Copson, Bryony Eccles, Tom Maishman et al. · JNCI Journal of the National Cancer Institute · 2013 · 214 citations · Full text

Medicine, Geriatric Medicine, Oncology +15